THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 281, NO. 23, pp. 15951–15958, June 9, 2006
Printed in the U.S.A.

Conserved Receptor-binding Domains of Lake Victoria Marburgvirus and Zaire Ebolavirus Bind a Common Receptor*

Received for publication, February 24, 2006, and in revised form, March 30, 2006 Published, JBC Papers in Press, April 4, 2006, DOI 10.1074/jbc.M601796200

Jens H. Kuhn[‡§1], Sheli R. Radoshitzky[‡], Alexander C. Guth[‡], Kelly L. Warfield[¶], Wenhui Li[‡], Martin J. Vincent[‖], Jonathan S. Towner[‖], Stuart T. Nichol[‖], Sina Bavari[¶], Hyeryun Choe[**], M. Javad Aman[¶], and Michael Farzan[‡2]

*From the [‡]Department of Microbiology and Molecular Genetics, Harvard Medical School, New England Primate Research Center, Southborough, Massachusetts 01772, the [§]Department of Biology, Chemistry, Pharmacy, Freie Universität Berlin, 14195 Berlin, Germany, the [¶]United States Army Medical Research Institute of Infectious Diseases, Ft. Detrick, Frederick, Maryland 21702, the [‖]Special Pathogens Branch, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30222, and the **Children's Hospital, Department of Pediatrics, Harvard Medical School, Boston, Massachusetts 02115*

The $GP_{1,2}$ envelope glycoproteins (GP) of filoviruses (marburg- and ebolaviruses) mediate cell-surface attachment, membrane fusion, and entry into permissive cells. Here we show that a 151-amino acid fragment of the Lake Victoria marburgvirus GP_1 subunit bound filovirus-permissive cell lines more efficiently than full-length GP_1. An homologous 148-amino acid fragment of the Zaire ebolavirus GP_1 subunit similarly bound the same cell lines more efficiently than a series of longer GP_1 truncation variants. Neither the marburgvirus GP_1 fragment nor that of ebolavirus bound a nonpermissive lymphocyte cell line. Both fragments specifically inhibited replication of infectious Zaire ebolavirus, as well as entry of retroviruses pseudotyped with either Lake Victoria marburgvirus or Zaire ebolavirus $GP_{1,2}$. These studies identify the receptor-binding domains of both viruses, indicate that these viruses utilize a common receptor, and suggest that a single small molecule or vaccine can be developed to inhibit infection of all filoviruses.

Filoviruses cause severe hemorrhagic fevers in human and nonhuman primates, with case fatality rates that reach 88%. The family *Filoviridae* contains two genera, *Marburgvirus* (species *Lake Victoria marburgvirus*) and *Ebolavirus* (species *Côte d'Ivoire ebolavirus*, *Reston ebolavirus*, *Sudan ebolavirus*, and *Zaire ebolavirus*) (1). Like all mononegaviruses, filoviruses are enveloped and contain nonsegmented single-stranded RNA genomes of negative polarity (2).

Filoviral envelope glycoproteins ($GP_{1,2}$)[3] are type 1 transmembrane and class I viral fusion proteins that mediate cell association, fusion of viral and cellular membranes, and entry of the viral core into the cytosol (3–5). The $GP_{1,2}$ precursor assembles as a trimer and is modified by *N*-glycosylation in the endoplasmic reticulum. Trafficking of the trimeric $GP_{1,2}$ precursor to the Golgi apparatus leads to refinement of *N*-glycosylation and addition of *O*-glycans (6–9). Furin-like proteases cleave the polypeptide into the ectodomain GP_1 and the transmembrane GP_2 subunits, both of which remain connected through an intramolecular disulfide bond ($GP_{1,2}$). Mature $GP_{1,2}$ trimers are then incorporated into virions during budding (6, 7, 10).

The filoviral GP_1 subunit mediates cell-surface receptor binding (8, 11). Approximately half of the molecular weight of GP_1 is because of *N*- and *O*-glycans, many of which are located at the C terminus of the subunit in a region described as the mucin-like domain (12, 13). This domain contributes to cytopathicity observed in $GP_{1,2}$-expressing cell lines and has been suggested to play a critical role in the pathogenesis of filoviral disease (14–16). However, its deletion enhances rather than decreases the efficiency of $GP_{1,2}$-mediated infection (13, 16–18). Receptor binding is followed by endocytosis of the virions (19), acidification of the endocytotic vesicle (4, 5, 20), and proteolytic processing of GP_1 by endosomal cathepsins (18, 21). Conformational changes in the filoviral GP_2 subunit facilitate lipid mixing and fusion of the viral and cellular membranes, in a sequence of steps thought similar to those mediated by orthomyxoviral and retroviral transmembrane proteins (22–25).

The host cell-surface receptor(s) for filoviruses have not yet been identified (26). However, the C-type lectin asialoglycoprotein receptor (27, 28), DC-SIGN (29, 30), hMGL (31), L-SIGN (29, 30), and LSECtin (32), as well as other molecules, including folate receptor-α (33) and β1 integrins (15), have been shown or suggested to enhance filovirus cell entry. Subtle differences between marburgvirus and ebolavirus infection efficiencies in different cell lines or following glycosidase or protease treatment have led to the suggestion that these viruses utilize distinct receptors or entry mechanisms (5).

Here we identify fragments of the Lake Victoria marburgvirus (Musoke strain; MARV-Mus) and Zaire ebolavirus (Mayinga stain; ZEBOV-May) GP_1 subunit that efficiently bound cells permissive to filovirus infection but not a nonpermissive lymphocyte cell line. Each fragment inhibited infection of retroviruses pseudotyped with either marburgvirus or ebolavirus $GP_{1,2}$. Both fragments also inhibited replication of infectious Zaire ebolavirus. Our data define homologous regions of otherwise divergent filoviruses that mediate association with a common receptor. Similarities in these receptor-binding domains may provide insight into the nature of this receptor and suggest vaccine and therapeutic approaches effective against all filoviruses.

EXPERIMENTAL PROCEDURES

Cells and Culture Conditions—African green monkey kidney (Vero E6) cells and Jurkat lymphocytes were obtained from the American

* This work was supported in part by Grant F_X012_04_RD_B from the Defense Threat Reduction Agency. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "*advertisement*" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

[1] Recipient of Career Development Fellowship Grant AI057159 from the New England Regional Center of Excellence/Biodefense and Infectious Diseases, Boston, MA.

[2] To whom correspondence should be addressed: Dept. of Microbiology and Molecular Genetics, Harvard Medical School, New England Primate Research Center, 1 Pine Hill Dr., Southborough, MA 01772-9102. Tel.: 508-624-8019; Fax: 508-786-3317; E-mail: farzan@hms.harvard.edu.

[3] The abbreviations used are: GP, glycoprotein; CoV, coronavirus; FITC, fluorescein isothiocyanate; GFP, green fluorescent protein; HIV-1, human immunodeficiency virus, type 1; MARV-Ang, Lake Victoria marburgvirus strain Angola; MARV-Mus, Lake Victoria marburgvirus strain Musoke; MLV, Moloney murine leukemia virus; PBS, phosphate-buffered saline; RBD, receptor-binding domain; SARS, severe acute respiratory syndrome; VSV, vesicular stomatitis Indiana virus; ZEBOV-May, Zaire ebolavirus strain Mayinga; ORF, open reading frame.

Report Documentation Page

Form Approved
OMB No. 0704-0188

1. REPORT DATE	2. REPORT TYPE	3. DATES COVERED
9 JUN 2006	**N/A**	**-**

4. TITLE AND SUBTITLE	5a. CONTRACT NUMBER
Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a shared receptor. Journal of Biological Chemistry 281:15951 - 15958	5b. GRANT NUMBER
	5c. PROGRAM ELEMENT NUMBER
6. AUTHOR(S)	5d. PROJECT NUMBER
Kuhn, JH Radoshitzky, SR Guth, AC Warfield, KL Li, W Vincent, MJ Towner, JS Nichol, ST Bavari, S Choe, H Aman, MJ Farzan, M	5e. TASK NUMBER
	5f. WORK UNIT NUMBER
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)	8. PERFORMING ORGANIZATION REPORT NUMBER
United States Army Medical Institute of Infectious Diseases, Fort Detrick, MD	**TR-06-035**
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)	10. SPONSOR/MONITOR'S ACRONYM(S)
	11. SPONSOR/MONITOR'S REPORT NUMBER(S)

12. DISTRIBUTION/AVAILABILITY STATEMENT
Approved for public release, distribution unlimited

13. SUPPLEMENTARY NOTES
The original document contains color images.

14. ABSTRACT
The GP1,2 envelope glycoproteins of filoviruses (marburg- and ebolaviruses) mediate cell-surface attachment, membrane fusion, and entry into permissive cells. Here we show that a 151-amino acid fragment of the Lake Victoria marburgvirus GP1 subunit bound filovirus-permissive cell lines more efficiently than full-length GP1. A homologous 148-amino acid fragment of the Zaire ebolavirus GP1 subunit similarly bound the same cell lines more efficiently than a series of longer GP1-truncation variants. Neither the marburgvirus GP1 fragment, nor that of ebolavirus, bound a non-permissive lymphocyte cell line. Both fragments specifically inhibited replication of infectious Zaire ebolavirus, as well as entry of retroviruses pseudotyped with either Lake Victoria marburgvirus or Zaire ebolavirus GP1,2. These studies identify the receptor-binding domains of both viruses, indicate that these viruses utilize a common receptor, and suggest that a single small molecule or vaccine can be developed to inhibit infection of all filoviruses.

15. SUBJECT TERMS
filovirus, ebola, marburg, envelope glycoproteins, membrane-activated compounds

16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			
unclassified	**unclassified**	**unclassified**	**SAR**	**8**	



FIGURE 1. **MARV-Mus and ZEBOV-May GP_1-Fc truncation variants.** *A*, representation of MARV-Mus GP_1 truncation variants in relation to the full-length MARV-Mus $GP_{1,2}$ envelope glycoprotein (residues 1–681). *sp*, signal peptide; *tm*, transmembrane domain. Cysteine residues, predicted or experimentally confirmed disulfide bonds, and potential *N*-glycosylation sites are indicated (13, 49). *RBD* indicates the truncation variant that most efficiently bound to cell surfaces of filovirus-permissive cells (see Fig. 2) and inhibited $GP_{1,2}$-mediated infection (Fig. 4). *B*, MARV-Mus GP_1-Fc, containing GP_1 residues 17–432, fused to the Fc region of human IgG, or truncation variants of GP_1-Fc, containing the indicated GP_1 residues, were purified from supernatants of transfected 293T cells. GP_1-Fc and truncation variants were normalized for expression, as shown by Coomassie staining. *C*, representation of ZEBOV-May GP_1 truncation variants in relation to the full-length ZEBOV-May $GP_{1,2}$ envelope glycoprotein (residues 1–676) as in *A*. *D*, ZEBOV-May GP_1-Fc, lacking its mucin-like domain fused to the Fc region of human IgG (33–308-Fc), truncation variants thereof, and control proteins (SARS-CoV RBD-Fc and HIV-1 gp120-Fc) were expressed and normalized as in *B*.

Type Culture Collection (ATCC numbers CRL-1586 and TIB-152, respectively). Human embryonic kidney 293T cells are a derivative of 293 cells (ATCC CRL1573) created by S. Haase and described originally as 293/*tsA1609*neo (34). Adherent cells (Vero E6 and 293T) were maintained in Dulbecco's modified Eagle's medium (Invitrogen) and Jurkat lymphocytes in RPMI 1640 medium (Invitrogen). All media were supplemented with 10% fetal bovine serum (Sigma), 100 IU/ml penicillin, and 100 μg/ml streptomycin (Cellgro), and cell cultures were maintained at 37 °C in a humidified 5% CO_2 atmosphere.

Construction of Filovirus Envelope Glycoprotein-encoding Genes and Variants—Codon-optimized Lake Victoria marburgvirus strain Musoke (MARV-Mus) open reading frames (ORFs) encoding GP_1 (amino acid residues 17-432) and $GP_{1,2}$ (amino acid residues 17-681) lacking signal sequences were synthesized and amplified by *de novo* recursive PCR, using overlapping DNA oligomers based on the MARV-Mus $GP_{1,2}$ protein sequence (GenBank™ accession number CAA781117). A codon-optimized Zaire ebolavirus strain Mayinga (ZEBOV-May) ORF encoding a mucin-like domain-deleted GP_1 truncation variant (amino acid residues 33–308) (13) was synthesized based on the ZEBOV-May $GP_{1,2}$ protein sequence (GenBank™ accession number NP_066246), using the same strategy. ORFs were ligated into a previously described pCDM8-derived expression vector (35), encoding the CD5 signal sequence upstream of the ORF insert, and the Fc region of human immunoglobulin G_1 downstream (MARV-Mus GP_1-(17–432)-Fc and ZEBOV-May GP_1-(33–308)-Fc). Vectors encoding N- and C-terminal truncation variants were generated by inverse PCR amplification using plasmids encoding MARV-Mus GP_1-(17–432)-Fc or ZEBOV-May GP_1-(33–308)-Fc as templates. An ORF encoding MARV-Mus $GP_{1,2}$ residues 17–681 was cloned into a variant of the pCDM8 expression vector encoding the CD5 signal sequence and a C-terminal C9 tag (amino acid sequence GTETSQVAPA) derived from the rhodopsin C terminus (MARV-Mus $GP_{1,2}$). Plasmid encoding a ZEBOV-May $GP_{1,2}$ variant lacking its



FIGURE 2. **Binding of MARV-Mus and ZEBOV-May GP_1-Fc truncation variants to the surface of nonhuman primate and human cells.** The indicated MARV-Mus (*A–C*) and ZEBOV-May GP_1-Fc constructs (*D–F*) and control proteins were incubated with filovirus-permissive African green monkey kidney (Vero E6) cells (*A* and *D*), filovirus-permissive 293T cells (*B* and *E*), and filovirus-nonpermissive Jurkat lymphocytes (*C* and *F*) and analyzed by flow cytometry using an Fc-specific FITC-conjugated secondary antibody. *Bars* indicate mean fluorescence intensity (*M.F.I.*) averages of two or more experiments. *Error bars* indicate standard deviations.

mucin-like domain, ZEBOV-May $GP_{1,2}$-(Δ309–489) (4), was generously provided by Dr. James Cunningham. Plasmids encoding MARV-Ang GP_1-Fc variants were generated by altering their equivalent MARV-Mus GP_1-Fc variants at codon 74 (T74A), using the QuikChange method (Stratagene).

Expression of Filovirus Envelope Glycoprotein Variants—For protein purification, 293T cells were transfected with plasmids encoding MARV-Mus GP_1-(17–432)-Fc or ZEBOV-May GP_1-(33–308)-Fc, their truncation variants, or control proteins (severe acute respiratory syndrome coronavirus strain Tor2 S(318–510)-Fc (SARS-CoV RBD-Fc)

and human immunodeficiency virus type 1 (HIV-1) strain ADA gp120-Fc (36, 37)), using the calcium-phosphate method. Cells were washed in Dulbecco's phosphate-buffered saline (Invitrogen) 6 h post-transfection and grown at 37 °C in 293 SFM II medium (Invitrogen) supplemented with 100 IU/ml penicillin and 100 μg/ml streptomycin, 100 μM minimum Eagle's medium nonessential amino acids solution (Invitrogen), 2 mM sodium butyrate (Sigma), and 4 mM L-glutamine (Sigma). Medium was harvested after 48 h, and cell debris was removed by centrifugation and filtration through a 0.22-μm pore size filter (Corning Glass). Proteins were precipitated with protein A-Sepharose fast flow beads (Amersham Biosciences) at 4 °C for 16 h in the presence of Complete protease inhibitor (Roche Applied Science). Beads were washed once with 30-bed volumes of 0.5 M sodium chloride/phosphate-buffered saline, pH 7.4 (NaCl, Fisher; PBS, Invitrogen), and once with 10-bed volumes of PBS. Proteins were eluted with 50 mM sodium citrate, 50 mM glycine, pH 2 (sodium citrate, Fisher; glycine, Bio-Rad), neutralized with sodium hydroxide (Fisher), dialyzed in PBS, and concentrated with Centricon centrifugal filter units (Millipore). Purified proteins were assayed for size and concentration by comparison to bovine serum albumin standards (Sigma) by SDS-PAGE followed by Bio-Safe Coomassie (Bio-Rad) staining, and by using the Micro BCA protein assay kit (Pierce) according to the manufacturer's instructions.

Cell Binding Assays—293T cells and Vero E6 cells were detached with PBS, 5 mM EDTA (Invitrogen) 48 h after plating, resuspended in an equal volume of PBS, 5 mM $MgCl_2$ (Sigma), and washed twice in PBS, 2% goat serum (Sigma). Jurkat lymphocytes were harvested and washed twice in PBS, 2% goat serum. GP_1-Fc constructs, truncation variants thereof, and control proteins were added to 5×10^5 cells to a final concentration of 100 nM and incubated on ice for 1.5 h. Cells were washed twice in PBS, 2% goat serum and incubated for 45 min on ice with a 1:40 dilution of goat Fc-specific fluorescein isothiocyanate (FITC)-conjugated anti-human IgG antibody (Sigma) in PBS, 2% goat serum. Cells were washed three times with PBS, 2% goat serum, once in PBS, and fixed with PBS, 2% formaldehyde (Sigma). Cell-surface binding of constructs was detected by flow cytometry with 10,000 events counted per sample. Base-line fluorescence was determined by measuring cells treated only with goat Fc-specific FITC-conjugated anti-human IgG antibody, which was then subtracted from binding values of the tested constructs and control proteins.

Infection Assay with Filovirus Envelope Glycoprotein-pseudotyped Retroviruses—To generate retroviral pseudotypes, 293T cells were transfected by the calcium phosphate method with plasmid encoding MARV-Mus $GP_{1,2}$, ZEBOV-May $GP_{1,2}$-(Δ309–489), or vesicular stomatitis Indiana virus (VSV) G protein, together with the pQCXIX vector (BD Biosciences) expressing green fluorescent protein (GFP), and plasmid encoding the Moloney murine leukemia virus (MLV) *gag* and *pol* genes (38) using equal concentrations of each plasmid. Cell supernatants were harvested 48 h post-transfection, cleared of cellular debris by centrifugation, filtered through a 0.45-μm pore size filter (Corning Glass), and stored at 4 °C. Supernatants containing pseudotyped viruses were added to 293T or Vero E6 cells in the presence or absence of the indicated concentrations of filovirus Fc truncation variants or control proteins. After 5 h, cells were washed once in PBS and replenished with fresh media. After 48 h, cells were imaged by fluorescent microscopy and detached with trypsin for analysis by flow cytometry.

Infection Assay with Recombinant Green Fluorescent Protein-expressing Zaire Ebolavirus—All experiments with infectious filovirus were performed under biosafety level 4 conditions. Vero E6 cells were infected with a GFP-expressing ZEBOV-May created by reverse genetics (39). Virus was incubated with cells at a multiplicity of infection equal to 1 for 1 h in the presence or absence of 800 nM of filovirus truncation variants or control protein. Virus was removed, cells were washed in PBS, and media and protein were replenished. After 48 h, cells were fixed in 10% neutral buffered formalin. After 3 days of fixation, cells were removed from the biosafety level 4 suite, and the percentage of GFP-expressing cells was measured with a Discovery-1 automated microscope (Molecular Devices Corp.) by measuring nine individual spots per well.



FIGURE 3. **Comparison of the cell surface-binding affinities of MARV-Mus and MARV-Ang GP_1-Fc truncation variants.** MARV-Ang GP_1-Fc truncation variants, differing from corresponding MARV-Mus GP_1-Fc truncation variants at residue 74 (threonine for MARV-Mus; alanine for MARV-Ang), were characterized as in Fig. 1. *A*, MARV-Ang GP_1-Fc truncation variants were normalized for expression and compared with the corresponding MARV-Mus truncation variants, as shown by Coomassie staining. *B*, the indicated MARV-Mus and MARV-Ang GP_1-Fc constructs were incubated with Vero E6 cells and analyzed by flow cytometry using an Fc-specific FITC-conjugated secondary antibody. *Bars* indicate mean fluorescence intensity (*M.F.I.*) averages of two or more experiments. *Error bars* indicate standard deviations.

RESULTS

MARV-Mus GP_1 Truncation Variant 38–188-Fc Efficiently Binds to Filovirus-permissive Cells—The envelope glycoproteins of a number of viruses include discrete, independently folded domains that bind cellular receptors as efficiently as their entire ectodomain regions. We sought to identify similar RBDs of MARV-Mus and ZEBOV-May. To determine the location of the MARV-Mus GP_1 RBD, we synthesized a codon-optimized gene encoding the full-length mature MARV-Mus GP_1 protein fused to the Fc region of human immunoglobulin G_1 at the C terminus (17–432-Fc). Four sets of seven truncation variants were created, starting at N-terminal residues 17, 38, 61, or 87 and ending at C-terminal residues 432, 308, 265, 230, 188, 167, or 134 (Fig. 1*A*). All 28 constructs expressed efficiently in 293T cells as Fc fusion proteins (Fig. 1*B*). Equivalent concentrations of each variant were incubated with MARV-Mus-permissive African green monkey kidney Vero E6 and human embryonic kidney 293T cells and with nonpermissive Jurkat lymphocytes (5), and cell-surface association was determined by



FIGURE 4. **MARV-Mus GP_1 truncation variant 38–188-Fc and ZEBOV-May GP_1 truncation variant 54–201-Fc inhibit MARV-Mus- or ZEBOV-May $GP_{1,2}$-mediated entry.** The indicated concentrations of MARV-Mus GP_1 truncation variant 38–188-Fc, ZEBOV-May GP_1 truncation variant 54–201-Fc, and SARS-CoV RBD-Fc protein were incubated with Vero E6 cells together with GFP-expressing MLV pseudotyped with either MARV-Mus $GP_{1,2}$ (*A* and *D*), mucin-like domain-deleted ZEBOV-May $GP_{1,2}$ (*B* and *E*), or VSV G (*C* and *F*). Entry of pseudotyped MLV was quantified by measuring green fluorescence using flow cytometry (*A–C*). *Bars* indicate mean fluorescence intensity (*M.F.I.*) averages of two or more experiments. *Error bars* indicate standard deviations.

flow cytometry (Fig. 2, *A–C*). The RBDs of the severe acute respiratory syndrome coronavirus (SARS-CoV) S protein (residues 318–510) and HIV-1 gp120, expressed as Fc fusion proteins (SARS-CoV RBD-Fc, gp120-Fc), were used as controls (36, 37). As reported previously, SARS-CoV RBD-Fc efficiently bound SARS-CoV-permissive Vero E6 cells but not 293T cells or Jurkat lymphocytes (40). Also as expected, gp120-Fc bound CD4-expressing Jurkat lymphocytes but not Vero E6 or 293T cells. All 28 MARV-Mus proteins bound to Vero E6 and 293T cells with varying efficiencies, whereas little or no association was observed with Jurkat lymphocytes in most cases. Successive truncation of the C termini of MARV-Mus GP_1 variants initiated with residues 17, 38, 61, or 87 led to successively increased cell-surface binding to Vero E6 cells, up through the C-terminal truncation at residue 188 (Fig. 2*A*). Further truncation beyond residue 188 decreased cell association. A single exception to this trend was observed with the 87–432-Fc variant, which bound Vero E6 cells with higher affinity than 87–308-Fc and 87–265-Fc. Variants initiated with residues 38, 61, and 87 bound more efficiently than those initiated with residue 17, with MARV-Mus-(38–188)-Fc consistently binding most efficiently to Vero E6 and 293T cells (Fig. 2*B*). These data identify a cell-binding region of MARV-Mus, located between GP_1 residues 38 and 188.

ZEBOV-May GP_1 Truncation Variant 54–201-Fc Efficiently Binds to Filovirus-permissive Cells—Deletion of the mucin-like domain has been demonstrated to markedly increase efficiency of ZEBOV $GP_{1,2}$-mediated infection (13, 16–18). To determine the location of the ZEBOV-May GP_1 RBD, we synthesized a codon-optimized gene encoding the mature ZEBOV GP_1 protein, lacking its mucin-like domain, and fused to the IgG1 Fc region (33–308-Fc). Three sets of four truncation variants were created, starting at N-terminal residues 33, 54, or 76 and ending at C-terminal residues 308, 201, 172, or 156 (Fig. 1*C*). With the exception of variant 76–172-Fc, all variants expressed efficiently (Fig. 1*D*). As with the MARV-Mus variants, equivalent concentrations of each variant were incubated with ZEBOV-May-permissive Vero E6 and 293T cells and with nonpermissive Jurkat lymphocytes, and cell association was again assayed by flow cytometry. All 11 ZEBOV-May GP_1 variants bound to Vero E6 and 293T cells, whereas binding to Jurkat lymphocytes was negligible in all cases (Fig. 2, *D–F*). ZEBOV-May GP_1 truncation variants showed a pattern of association to Vero E6 and 293T cells similar to that observed with MARV-Mus variants. In particular,

54–201-Fc and 76–201-Fc bound more efficiently than all other ZEBOV-May GP_1 variants assayed, with 54–201-Fc binding slightly but consistently better than 76–201-Fc to Vero E6 cells (Fig. 2, *D–E*). These data identify a cell-binding region of ZEBOV-May, located between GP_1 residues 54 and 201, which corresponds to the cell-binding region of MARV-Mus.

MARV Strains Angola and Musoke GP_1 Truncation Variants Bind to Filovirus-permissive Cells with Comparable Efficiency—The largest and most severe marburgvirus disease outbreak to date occurred in Angola in early 2005 (41, 42). The envelope glycoprotein amino acid sequence of the strain responsible for this outbreak, MARV Angola (MARV-Ang), is homologous to that of the MARV-Mus strain (43). In particular, a comparison between MARV-Mus GP_1 amino acid residues 38–188 with the corresponding region of MARV-Ang yielded only one amino acid change, threonine 74 to alanine (T74A). This alteration was introduced into four MARV-Mus GP_1 truncation variants (MARV-Ang GP_1-(38–188)-Fc, -(38–167)-Fc, -(61–188)-Fc, and -(61–167)-Fc; see Fig. 3*A*). Cell association of each of these variants was compared with those of MARV-Mus. Each MARV-Ang variant bound Vero E6 cells slightly less efficiently than its MARV-Mus counterpart (Fig. 3*B*). These data largely exclude the possibility that more efficient cellular association of the MARV-Ang cell-binding region contributes to increased severity of disease.

Both MARV-Mus and ZEBOV-May GP_1 Cell-binding Regions Inhibit Entry of Retroviruses Pseudotyped with the $GP_{1,2}$ of Either Filovirus—To determine whether the identified GP_1 cell-binding regions associated with factors necessary for infection, we assayed the ability of MARV-Mus-(38–188)-Fc and ZEBOV-May-(54–201)-Fc to inhibit entry of pseudotyped retroviruses. A Moloney murine leukemia virus vector expressing GFP was pseudotyped with the $GP_{1,2}$ of MARV-Mus (MARV/MLV), a mucin-like domain-deleted $GP_{1,2}$ of ZEBOV-May (ZEBOV/MLV), or with the G protein of vesicular stomatitis Indiana virus (VSV/MLV). Vero E6 cells were incubated with these pseudotyped retroviruses and varying concentrations of MARV-Mus-(38–188)-Fc, ZEBOV-May-(54–201)-Fc, or SARS-CoV RBD-Fc (Fig. 4, *A–C*). No Fc fusion protein inhibited VSV/MLV, but both MARV-Mus-(38–188)-Fc and ZEBOV-May-(54–201)-Fc efficiently inhibited both MARV/MLV and ZEBOV/MLV. SARS-CoV RBD-Fc did not inhibit infection of either pseudotyped virus. MARV-Mus-(38–188) was the more potent of the two cellular binding domains, inhibiting MARV/MLV and ZEBOV/MLV with an apparent IC_{50} of 50–100 nM in this assay (Fig. 4*A*). These data indicate that MARV-Mus-(38–188)-Fc and ZEBOV-May-(54–201)-Fc bind specifically to a common cell-surface factor critical to filovirus entry. Accordingly, and by analogy with other viral entry proteins, we hereafter refer to these cell-binding regions of MARV-Mus and ZEBOV-May GP_1 as RBDs.

MARV-Mus-(38–188)-Fc Inhibits MARV/MLV Entry More Efficiently than Other GP_1 Truncation Variants—We investigated whether the cell-binding efficiency of MARV-Mus and MARV-Ang GP_1 truncation variants correlated with their ability to inhibit entry of pseudotyped retroviruses (Fig. 5). Vero E6 cells were incubated with the indicated GP_1 variants together with VSV/MLV or MARV/MLV. None of the GP_1 variants inhibited VSV/MLV entry, whereas most of the MARV-Mus GP_1 variants assayed inhibited that of MARV/MLV (Fig. 5). Some variation between entry inhibition and cell binding was observed. Notably, full-length MARV-Mus GP_1-(17–432)-Fc inhibited MARV/MLV entry as efficiently as the defined receptor-binding domains of MARV-Mus and MARV-Ang-(38–188)-Fc. Apart from this interesting exception, the MARV-Mus RBD inhibited entry more efficiently than any other GP_1 variant assayed (Fig. 5). We speculate that the mucin-like domain of full-length



FIGURE 5. **Comparison of the inhibitory effect of MARV-Mus and MARV-Ang GP_1-Fc truncation variants on cell entry of MLV pseudotyped with MARV-Mus $GP_{1,2}$.** 100 nM of the indicated MARV-Mus or MARV-Ang GP_1-Fc truncation variants or SARS-CoV RBD-Fc were incubated with Vero E6 cells together with GFP-expressing MLV pseudotyped with MARV-Mus $GP_{1,2}$ or VSV G. Entry of pseudotyped MLV was quantified by measuring green fluorescence using flow cytometry. *Bars* indicate mean fluorescence intensity (*M.F.I.*) averages of two or more experiments. *Error bars* indicate standard deviations.

GP_1 mediates a lower affinity interaction with Vero E6 cells, which may contribute to inhibition of entry but may be more susceptible to the wash steps of the binding assay shown in Fig. 2. Alternatively, partial misfolding of the longer truncation variants may impair cell surface association. Our data show that variants of the MARV-Mus RBD that are slightly longer or shorter inhibit MARV/MLV less efficiently, consistent with their relatively lower affinity for filovirus-permissive cell lines.

MARV-Mus-(38–188)-Fc and ZEBOV-May-(54–201) Inhibit Replication of Infectious Zaire Ebolavirus—To determine whether the filovirus RBDs also inhibited infectious filovirus, Vero E6 cells were incubated with an infectious Zaire ebolavirus modified to express GFP (39), at a multiplicity of infection of 1, together with MARV-Mus-(38–188)-Fc, ZEBOV-May-(54–201)-Fc, or SARS-CoV RBD-Fc. As expected, viral replication, measured as percentage of infected cells, was specifically inhibited by both filovirus RBDs but not by that of SARS-CoV (Fig. 6). Higher concentrations were required to inhibit infectious filovirus than the concentrations used to inhibit pseudotyped retroviruses (Figs. 4 and 6). These higher concentrations may be necessary to interfere with the greater number of $GP_{1,2}$ molecules present on the filamentous filoviruses, compared with the significantly smaller retroviral pseudotypes. As observed with pseudotyped retroviruses, the MARV-Mus RBD inhibited infectious Zaire ebolavirus more efficiently than the ZEBOV-May RBD (Fig. 6). Similar inhibition of Zaire ebolavirus replication was observed in primary monocyte-derived human dendritic cells treated with ZEBOV-May or MARV-Mus RBDs (data not shown). The efficiency with which the MARV-Mus RBD inhibited ebolavirus replication is consistent with the utilization of a common entry factor by both marburg- and ebolaviruses.

DISCUSSION

Enveloped viruses require specific proteins on the virion surface that mediate cell attachment and fusion of the viral and cellular membranes. Viral class I fusion proteins are typically composed of two functionally distinct domains or subunits (44, 45). The N-terminal domain, GP_1 in the case of filoviruses, mediates cell attachment and receptor associa-

tion (8, 11). Viral entry proteins attach to a number of cell-surface molecules, including glycosaminoglycans and C-type lectins, and these attachments frequently make substantial contributions to the efficiency of viral entry (30, 46–48). More critically, most enveloped viruses require one or more cellular receptors to initiate membrane fusion. Receptor-binding regions of viral fusion proteins are typically the most important antibody-neutralizing epitopes on the virion, because of the functional importance of and limited variation in this region (44, 45). In some cases, such as murine and feline leukemia viruses and SARS coronavirus, the receptor-binding region is localized to a discrete, independently folded domain that can efficiently bind the cellular receptor and inhibit infection (37, 50, 51). These domains themselves also can be sufficient to elicit protective neutralizing antibodies (45, 52).



FIGURE 6. **MARV-Mus GP_1 truncation variant 38–188-Fc and ZEBOV-May GP_1 truncation variant 54–201-Fc inhibit replication of infectious filovirus.** 800 nM of MARV-Mus GP_1 truncation variant 38–188-Fc, ZEBOV-May GP_1 truncation variant 54–201-Fc, or SARS-CoV RBD-Fc were incubated with recombinant, GFP-expressing Zaire ebolavirus. Infection was quantified by measuring green fluorescence by using Discovery-1 automated microscopy. *Bars* indicate percentage of infected cells, averaged over three experiments. *Error bars* indicate standard deviations.

Here we defined small domains of the GP_1 proteins of two divergent filoviruses that bind filovirus-permissive cells. Several lines of evidence suggest that these domains bind a cellular receptor rather than a less specific attachment factor. First, these domains do not associate with a cell line refractory to filovirus infection. Second, they associate with filovirus-permissive cells more efficiently than larger and more heavily glycosylated GP_1 variants. Indeed, ZEBOV-May-(54–201)-Fc includes no *N*-glycosylation sites that could associate with a cell-surface lectin-like molecule (MARV-Mus-(38–188)-Fc has two potential *N*-glycosylation sites). Third, each domain efficiently inhibits entry mediated by their respective $GP_{1,2}$ at 50–200 nM, indicating that they associate with moderately high affinity and specifically with a factor critical to entry. Finally, they include the most highly conserved region of filovirus GP_1 (17). The conservation of this region among all marburg- and ebolaviruses raises the possibility that ZEBOV-May-(54–201)-Fc and MARV-Mus-(38–188)-Fc can be used to elicit antibodies that protect against most filoviruses (see Fig. 7 for alignment of the MARV and ZEBOV RBD).

Previous studies of Zaire ebolavirus $GP_{1,2}$ are also consistent with association of these domains with a specific cellular receptor. Medina *et al.* (53) have observed that a Zaire ebolavirus $GP_{1,2}$ lacking residues 241–496 nonetheless retained its ability to mediate entry of a pseudotyped retrovirus. Manicassamy *et al.* (17) have shown that short deletions and point mutations of Zaire ebolavirus $GP_{1,2}$, some of them between residues 54 and 201, interfere with $GP_{1,2}$-mediated infection. Finally, Chandran *et al.* and Schornberg *et al.* demonstrated that digestion of Zaire ebolavirus $GP_{1,2}$-pseudotyped VSV with cathepsin B or L removes all but an 18–19-kDa fragment of GP_1, likely localized at the N terminus. This fragment remained attached to GP_2 through a disulfide bond and still mediated infection (18, 21).

Although the genomic organization of marburg- and ebolaviruses is similar, and although they cause similar diseases of comparable severity, it has not been clear whether all filoviruses utilize a common receptor. Several observations in the literature raised the possibility that their receptors or entry mechanisms are distinct. Lake Victoria marburgvirus has been reported to be less susceptible than Zaire ebolavirus to treatment of target cells with proteases and glycosidases (5). Electron micrographs of the virus entering cells have been used to suggest that Lake Victoria marburgvirus enters cells differently than Zaire ebolavirus (54), although earlier work suggests otherwise (19). Some variation in the relative efficiencies with which Lake Victoria marburg- and Zaire ebo-



FIGURE 7. **Sequence alignment of MARV-Mus and ZEBOV-May receptor-binding domains.** Sequence alignment of the best cell surface-binding and $GP_{1,2}$-mediated entry-inhibiting filovirus GP_1 truncation variants MARV-Mus-(38–188) and ZEBOV-May-(54–201). Residues in *gray* indicate identical residues. A disulfide bond common to both receptor-binding domains is indicated with a *bracket,* as is a disulfide bond present only in ebolaviruses. Threonine 74 of MARV-Mus GP_1, which is an alanine in MARV-Ang GP_1, is *highlighted*. *Arrows* indicate further truncations that reduced cell-surface binding and inhibition of $GP_{1,2}$-mediated entry.

lavirus $GP_{1,2}$ mediated entry in different cell lines also raised the possibility of distinct receptors (5).

Despite these observations, our data indicate that at least one of the receptors required by each filovirus is common to both. This situation is not unprecedented. For example, SARS coronavirus and human coronavirus NL63 enter cells by distinct mechanisms, although angiotensin-converting enzyme 2 is an obligate receptor for both (55, 56). Further study will be necessary to clarify whether the downstream entry processes of marburg- and ebolaviruses are similarly distinct.

The conservation of the filovirus receptor-binding domains and their utilization of a common receptor raise the possibility that a vaccine could elicit antibodies that neutralize both marburg- and ebolaviruses, although cross-protective antibodies have not been described to date. Our observations also indicate that small molecules could be designed to inhibit entry of all filoviruses. Such cross-protection would be useful in the rapid containment of a novel filovirus epidemic.

Acknowledgments—We thank Dina Uzri (Harvard Medical School, Boston, MA) for help with plasmid construction; Gordon Ruthel and Jason Paragas (United States Army Medical Research Institute of Infectious Diseases, Frederick, MD) for analyzing samples with the Discovery-1 microscope and providing GFP-ZEBOV-May, respectively; Bobbie Rae Erickson, Darcy Bawiec, and Marina Khristova (Centers for Disease Control and Prevention, Atlanta, GA) for assistance with the genomic sequencing of MARV-Ang; Gerald A. Beltz (New England Regional Center of Excellence/Biodefense and Infectious Diseases, Boston, MA) for critically reading the manuscript; and James Cunningham and Kartik Chandran (Harvard Medical School, Boston, MA) for reagents and insight.

REFERENCES

1. Feldmann, H., Geisbert, T. W., Jahrling, P. B., Klenk, H.-D., Netesov, S. V., Peters, C. J., Sanchez, A., Swanepoel, R., and Volchkov, V. E. (2005) in *Virus Taxonomy, Eighth Report of the International Committee on Taxonomy of Viruses* (Fauquet, C. M., Mayo, M. A., Maniloff, J., Desselberger, U., and Ball, L. A., eds) pp. 645–653, Elsevier/Academic Press, San Diego
2. Pringle, C. R., and Easton, A. J. (1997) *Semin. Virol.* **8,** 49–57
3. Takada, A., Robison, C., Goto, H., Sanchez, A., Murti, K. G., Whitt, M. A., and Kawaoka, Y. (1997) *Proc. Natl. Acad. Sci. U. S. A.* **94,** 14764–14769
4. Wool-Lewis, R. J., and Bates, P. (1998) *J. Virol.* **72,** 3155–3160
5. Chan, S. Y., Speck, R. F., Ma, M. C., and Goldsmith, M. A. (2000) *J. Virol.* **74,** 4933–4937
6. Volchkov, V. E., Feldmann, H., Volchkova, V. E., and Klenk, H.-D. (1998) *Proc. Natl. Acad. Sci. U. S. A.* **95,** 5762–5767
7. Volchkov, V. E., Volchkova, V. A., Ströher, U., Becker, S., Dolnik, O., Cieplik, M., Garten, W., Klenk, H.-D., and Feldmann, H. (2000) *Virology* **268,** 1–6
8. Feldmann, H., Volchkov, V. E., Volchkova, V. A., Ströher, U., and Klenk, H.-D. (2001) *J. Gen. Virol.* **82,** 2839–2848
9. Becker, S., Klenk, H.-D., and Mühlberger, E. (1996) *Virology* **225,** 145–155
10. Kolesnikova, L., Berghöfer, B., Bamberg, S., and Becker, S. (2004) *J. Virol.* **78,** 12277–12287
11. Sanchez, A., Kiley, M. P., Holloway, B. P., and Auperin, D. D. (1993) *Virus Res.* **29,** 215–240
12. Sanchez, A., Yang, Z.-Y., Xu, L., Nabel, G. J., Crews, T., and Peters, C. J. (1998) *J. Virol.* **72,** 6442–6447
13. Jeffers, S. A., Sanders, D. A., and Sanchez, A. (2002) *J. Virol.* **76,** 12463–12472
14. Simmons, G., Wool-Lewis, R. J., Baribaud, F., Netter, R. C., and Bates, P. (2002) *J. Virol.* **76,** 2518–2528
15. Takada, A., Watanabe, S., Ito, H., Okazaki, K., Kida, H., and Kawaoka, Y. (2000) *Virology* **278,** 20–26
16. Yang, Z.-Y., Duckers, H. J., Sullivan, N. J., Sanchez, A., Nabel, E. G., and Nabel, G. J. (2000) *Nat. Med.* **6,** 886–889
17. Manicassamy, B., Wang, J., Jiang, H., and Rong, L. (2005) *J. Virol.* **79,** 4793–4805
18. Chandran, K., Sullivan, N. J., Felbor, U., Whelan, S. P., and Cunningham, J. M. (2005) *Science* **308,** 1643–1645
19. Geisbert, T. W., and Jahrling, P. B. (1995) *Virus Res.* **39,** 129–150
20. Maryankova, R. F., Glushakova, S. E., Ryzhik, E. V., and Lukashevich, I. S. (1993) *Vopr. Virusol.* **38,** 74–76
21. Schornberg, K., Matsuyama, S., Kabsch, K., Delos, S., Bouton, A., and White, J. (2006) *J. Virol.* **80,** 4147–4178
22. Gallaher, W. R. (1996) *Cell* **85,** 477–478
23. Ito, H. S., Watanabe, S., Sanchez, A., Whitt, M. A., and Kawaoka, Y. (1999) *J. Virol.* **73,** 8907–8912
24. Ruiz-Argüello, M. B., Goñi, F. M., Pereira, F. B., and Nieva, J. L. (1998) *J. Virol.* **72,** 1775–1781
25. Watanabe, S., Takada, A., Watanabe, T., Ito, H., Kida, H., and Kawaoka, Y. (2000) *J. Virol.* **74,** 10194–10201
26. Simmons, G., Rennekamp, A. J., Chai, N., Vandenberghe, L. H., Riley, J. L., and Bates, P. (2003) *J. Virol.* **77,** 13433–13438
27. Becker, S., Spiess, M., and Klenk, H.-D. (1995) *J. Gen. Virol.* **76,** 393–399
28. Lin, G., Simmons, G., Pöhlmann, S., Baribaud, F., Ni, H., Leslie, G. J., Haggarty, B. S., Bates, P., Weissman, D., Hoxie, J. A., and Doms, R. W. (2003) *J. Virol.* **77,** 1337–1346
29. Simmons, G., Reeves, J. D., Grogan, C. C., Vandenbergh, L. H., Baribaud, F., Whitbeck, J. C., Burke, E., Buchmeier, M. J., Soilleux, E. J., Riley, J. L., Doms, R. W., Bates, P., and Pöhlmann, S. (2003) *Virology* **305,** 115–123
30. Marzi, A., Gramberg, T., Simmons, G., Möller, P., Rennekamp, A. J., Krumbiegel, M., Geier, M., Eisemann, J., Turza, N., Saunier, B., Steinkasserer, A., Becker, S., Bates, P., Hofmann, H., and Pöhlmann, S. (2004) *J. Virol.* **78,** 12090–12095
31. Takada, A., Fujioka, K., Tsuiji, M., Morikawa, A., Higashi, N., Ebihara, H., Kobasa, D., Feldmann, H., Irimura, T., and Kawaoka, Y. (2004) *J. Virol.* **78,** 2943–2947
32. Gramberg, T., Hofmann, H., Möller, P., Lalor, P. F., Marzi, A., Geier, M., Krumbiegel, M., Winkler, T., Kirchhoff, F., Adams, D. H., Becker, S., Münch, J., and Pöhlmann, S. (2005) *Virology* **340,** 224–236
33. Chan, S. Y., Empig, C. J., Welte, F. J., Speck, R. F., Schmaljohn, A., Kreisberg, J. F., and Goldsmith, M. A. (2001) *Cell* **106,** 117–126
34. DuBridge, R. B., Tang, P., Hsia, H. C., Leong, P. M., Miller, J. H., and Calos, M. P. (1987) *Mol. Cell. Biol.* **7,** 379–387
35. Farzan, M., Mirzabekov, T., Kolchinsky, P., Wyatt, R., Cayabyab, M., Gerard, N. P., Gerard, C., Sodroski, J., and Choe, H. (1999) *Cell* **96,** 667–676
36. Choe, H., Li, W., Wright, P. L., Vasilieva, N., Venturi, M., Huang, C. C., Grundner, C., Dorfman, T., Zwick, M. B., Wang, L., Rosenberg, E. S., Kwong, P. D., Burton, D. R., Robinson, J. E., Sodroski, J. G., and Farzan, M. (2003) *Cell* **114,** 161–170
37. Wong, S. K., Li, W., Moore, M. J., Choe, H., and Farzan, M. (2004) *J. Biol. Chem.* **279,** 3197–3201
38. Moore, M. J., Dorfman, T., Li, W., Wong, S. K., Li, Y., Kuhn, J. H., Coderre, J., Vasilieva, N., Han, Z., Greenough, T. C., Farzan, M., and Choe, H. (2004) *J. Virol.* **78,** 10628–10635
39. Towner, J. S., Paragas, J., Dover, J. E., Gupta, M., Goldsmith, C. S., Huggins, J. W., and Nichol, S. T. (2005) *Virology* **332,** 20–27
40. Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., Choe, H., and Farzan, M. (2003) *Nature* **426,** 450–454
41. Hovette, P. (2005) *Méd. Trop.* (*Mars.*) **65,** 127–128
42. World Health Organization. (2005) *Wkly. Epidemiol. Rec.* **80,** 298
43. Towner, J. S., Khristova, M. L., Sealy, T. K., Vincent, M. J., Erickson, B. R., Bawiec, D. A., Hartman, A. L., Comer, J. A., Zaki, S. R., Ströher, U., Gomes da Silva, F., del Castillo, F., Rollin, P., Ksiazek, T. G., and Nichol, S. T. (2006) *J. Virol.,* in press
44. Dimitrov, D. S. (2004) *Nat. Rev. Microbiol.* **2,** 109–122
45. Eckert, D. M., and Kim, P. S. (2001) *Annu. Rev. Biochem.* **70,** 777–810
46. Baribaud, F., Doms, R. W., and Pöhlmann, S. (2002) *Expert Opin. Ther. Targets* **6,** 423–431
47. Ohshiro, Y., Murakami, T., Matsuda, K., Nishioka, K., Yoshida, K., and Yamamoto, N. (1996) *Microbiol. Immunol.* **40,** 827–835
48. Geijtenbeek, T. B. H., Kwon, D. S., Torensma, R., van Vliet, S. J., van Duijnhoven, G. C. F., Middel, J., Cornelissen, I. L. M. H. A., Nottet, H. S. L. M., KewalRamani, V. N., Littman, D. R., Figdor, C. G., and van Kooyk, Y. (2000) *Cell* **100,** 587–597
49. He, Y., Lu, H., Siddiqui, P., Zhou, Y., and Jiang, S. (2005) *J. Immunol.* **174,** 4908–4915
50. Barnett, A. L., Wensel, D. L., Li, W., Fass, D., and Cunningham, J. M. (2003) *J. Virol.* **77,** 2717–2729
51. Fass, D., Davey, R. A., Hamson, C. A., Kim, P. S., Cunningham, J. M., and Berger, J. M. (1997) *Science* **277,** 1662–1666
52. Medina, M. F., Kobinger, G. P., Rux, J., Gasmi, M., Looney, D. J., Bates, P., and Wilson, J. M. (2003) *Mol. Ther.* **8,** 777–789
53. Ryabchikova, E. I., and Price, B. B. S. (2004) *Ebola and Marburg Viruses, A View of Infection Using Electron Microscopy*, Battelle Press, Columbus, OH
54. Hofmann, H., Pyrc, K., van der Hoek, L., Geier, M., Berkhout, B., and Pohlmann, S. (2005) *Proc. Natl. Acad. Sci. U. S. A.* **102,** 7988–7993
55. Huang, I. C., Bosch, B. J., Li, F., Li, W., Lee, K. H., Ghiran, S., Vasilieva, N., Dermody, T. S., Harrison, S. C., Dormitzer, P. R., Farzan, M., Rottier, P. J., and Choe, H. (2006) *J. Biol. Chem.* **281,** 3198–3203
56. Volchkov, V., Volchkova, V., Dolnik, O., Feldmann, H., and Klenk, H.-D. (2004) in *Ebola and Marburg Viruses* (Klenk, H.-D., and Feldmann, H., eds) pp. 59–89, Horizon Bioscience, Wymondham, Norfolk, UK